Want to see HK:8622 full AI Analyst Report?
Huakang Biomedical Holdings Company Limited (8622) Ratios
0 Followers
Huakang Biomedical Holdings Company Limited Ratios
HK:8622's free cash flow for Q2 2026 was ¥-2.40M. For the 2026 fiscal year, HK:8622's free cash flow was increased by ¥0.00 and operating cash flow was ¥-2.40M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.88 | 4.90 | 4.08 | 5.46 | 6.21 |
| Quick Ratio | 3.60 | 4.66 | 3.82 | 5.14 | 5.73 |
| Cash Ratio | 2.50 | 2.82 | 2.51 | 3.40 | 4.19 |
| Solvency Ratio | -0.08 | -0.23 | -0.18 | 0.01 | -0.14 |
| Operating Cash Flow Ratio | -0.15 | -0.27 | -0.00 | 0.13 | -0.28 |
| Short-Term Operating Cash Flow Coverage | -0.61 | -1.05 | -0.02 | 0.91 | -23.54 |
| Net Current Asset Value | ¥ 41.83M | ¥ 43.55M | ¥ 39.14M | ¥ 43.55M | ¥ 44.31M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.06 | 0.08 | 0.03 | 0.03 |
| Debt-to-Equity Ratio | 0.10 | 0.08 | 0.10 | 0.03 | 0.03 |
| Debt-to-Capital Ratio | 0.09 | 0.07 | 0.09 | 0.03 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.30 | 1.21 | 1.28 | 1.17 | 1.16 |
| Debt Service Coverage Ratio | -1.09 | -1.14 | -0.88 | 0.08 | -5.76 |
| Interest Coverage Ratio | -32.59 | -58.27 | -139.45 | -92.55 | -44.88 |
| Debt to Market Cap | 0.02 | 0.04 | 0.07 | 0.02 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Net Debt to EBITDA | 7.66 | 8.04 | 10.90 | -167.16 | 40.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 62.83% | 67.32% | 65.34% | 66.77% | 62.98% |
| EBIT Margin | -27.90% | -19.76% | -23.26% | -11.65% | -14.55% |
| EBITDA Margin | -14.76% | -13.45% | -10.35% | 0.74% | -3.26% |
| Operating Profit Margin | -27.61% | -19.76% | -30.01% | -20.09% | -17.52% |
| Pretax Profit Margin | -17.73% | -16.40% | -23.48% | -11.87% | -14.94% |
| Net Profit Margin | -17.70% | -16.40% | -23.48% | -12.14% | -16.15% |
| Continuous Operations Profit Margin | -17.73% | -16.40% | -23.48% | -12.14% | -16.15% |
| Net Income Per EBT | 99.86% | 100.00% | 100.00% | 102.26% | 108.12% |
| EBT Per EBIT | 64.19% | 82.98% | 78.23% | 59.08% | 85.26% |
| Return on Assets (ROA) | -7.51% | -6.38% | -8.85% | -4.63% | -6.29% |
| Return on Equity (ROE) | -9.79% | -7.69% | -11.33% | -5.44% | -7.31% |
| Return on Capital Employed (ROCE) | -15.05% | -9.27% | -14.15% | -8.99% | -7.84% |
| Return on Invested Capital (ROIC) | -13.91% | -8.62% | -13.16% | -8.71% | -7.69% |
| Return on Tangible Assets | -7.60% | -6.52% | -9.15% | -4.84% | -6.59% |
| Earnings Yield | -2.56% | -6.12% | -14.34% | -4.65% | -5.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.68 | 2.55 | 2.54 | 2.67 | 2.78 |
| Payables Turnover | 16.29 | 12.48 | 13.38 | 10.15 | 13.49 |
| Inventory Turnover | 2.54 | 3.05 | 2.51 | 2.70 | 2.30 |
| Fixed Asset Turnover | 3.30 | 2.80 | 2.53 | 3.06 | 2.52 |
| Asset Turnover | 0.42 | 0.39 | 0.38 | 0.38 | 0.39 |
| Working Capital Turnover Ratio | 0.66 | 0.60 | 0.59 | 0.57 | 0.55 |
| Cash Conversion Cycle | 257.65 | 233.62 | 261.39 | 235.65 | 263.14 |
| Days of Sales Outstanding | 136.15 | 143.20 | 143.50 | 136.46 | 131.31 |
| Days of Inventory Outstanding | 143.90 | 119.67 | 145.17 | 135.14 | 158.89 |
| Days of Payables Outstanding | 22.40 | 29.25 | 27.28 | 35.95 | 27.06 |
| Operating Cycle | 280.05 | 262.87 | 288.67 | 271.60 | 290.20 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.01 | -0.00 | 0.00 | -0.01 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.00 | 0.00 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -2.04 | -1.54 | -0.03 | 1.59 | -1.02 |
| Capital Expenditure Coverage Ratio | -2.04 | -1.54 | -0.03 | 1.59 | -1.02 |
| Operating Cash Flow Coverage Ratio | -0.45 | -0.75 | -0.01 | 0.69 | -1.33 |
| Operating Cash Flow to Sales Ratio | -0.08 | -0.12 | -0.00 | 0.05 | -0.09 |
| Free Cash Flow Yield | -1.68% | -7.43% | -3.84% | 0.72% | -5.83% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -39.07 | -16.35 | -6.98 | -21.50 | -19.14 |
| Price-to-Sales (P/S) Ratio | 6.93 | 2.68 | 1.64 | 2.61 | 3.09 |
| Price-to-Book (P/B) Ratio | 3.83 | 1.26 | 0.79 | 1.17 | 1.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -59.52 | -13.45 | -26.02 | 139.16 | -17.16 |
| Price-to-Operating Cash Flow Ratio | -88.68 | -22.21 | -840.20 | 51.40 | -33.97 |
| Price-to-Earnings Growth (PEG) Ratio | -2.40 | 0.43 | -0.08 | 0.78 | 0.30 |
| Enterprise Value Multiple | -39.26 | -11.89 | -4.91 | 184.44 | -54.42 |
| Enterprise Value | 163.93M | 40.56M | 12.53M | 34.67M | 46.37M |
| EV to EBITDA | -39.26 | -11.89 | -4.91 | 184.44 | -54.42 |
| EV to Sales | 5.80 | 1.60 | 0.51 | 1.37 | 1.77 |
| EV to Free Cash Flow | -49.80 | -8.03 | -8.08 | 73.00 | -9.85 |
| EV to Operating Cash Flow | -74.20 | -13.25 | -261.05 | 26.96 | -19.50 |
| Tangible Book Value Per Share | 0.10 | 0.11 | 0.12 | 0.13 | 0.14 |
| Shareholders’ Equity Per Share | 0.10 | 0.11 | 0.12 | 0.14 | 0.14 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.02 | -0.08 |
| Revenue Per Share | 0.06 | 0.05 | 0.06 | 0.06 | 0.07 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.02 | 1.08 |
| Interest Burden | 0.64 | 0.83 | 1.01 | 1.02 | 1.03 |
| Research & Development to Revenue | 0.14 | 0.11 | 0.10 | 0.10 | 0.09 |
| SG&A to Revenue | 0.76 | 0.76 | 0.40 | 0.39 | 0.36 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.45 | 0.74 | 0.01 | -0.43 | 0.61 |
Currency in CNY
